Department of Head and Neck Area, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Shenyang, China.
Eur Rev Med Pharmacol Sci. 2020 Nov;24(21):11148-11153. doi: 10.26355/eurrev_202011_23602.
The aim of this study was to investigate the expression of long non-coding RNA (lncRNA)-ATB in laryngeal carcinoma (LNCa) and its relationship with the prognosis.
The expression of lncRNA-ATB was examined in laryngeal carcinoma tissue specimens, as well as in normal ones by quantitative real-time polymerase chain reaction (qRT-PCR), and the interplay between lncRNA-ATB levels and clinical indicators was analyzed. In addition, the diagnostic value of lncRNA-ATB for LNCa was assessed by receiver operating characteristic (ROC) curve analysis. The patients were followed up for 5 years and the survival analysis was conducted by Kaplan-Meier test. Finally, the Cox regression model was used to analyze the factors affecting the prognosis of patients.
LncRNA-ATB expression was markedly enhanced in laryngeal carcinoma tissue samples compared to the corresponding normal ones, which was relevant to T grade and clinical stage. For the diagnosis of laryngeal carcinoma using lncRNA-ATB, the area under the ROC curve (AUC) was 0.8672, the diagnostic threshold was 3.895, and the sensitivity and specificity were 83.02% and 76.42%, respectively. In addition, the overall survival rate of patients with high expression of lncRNA-ATB was markedly lower than those in low expression group. Meanwhile, T grade, clinical stage and lncRNA-ATB are found as three independent factors influencing the prognosis of LNCa.
LncRNA-ATB was highly expressed in laryngeal carcinoma tissues, which was not conducive to the prognosis of patients. Therefore, this molecular marker has potential to become a new biomarker for the diagnosis and prognosis prediction of patients with LNCa.
本研究旨在探讨长链非编码 RNA（lncRNA）-ATB 在喉癌（LNCa）中的表达及其与预后的关系。
采用实时定量聚合酶链反应（qRT-PCR）检测喉癌组织标本及相应正常组织中 lncRNA-ATB 的表达，并分析 lncRNA-ATB 水平与临床指标的相互关系。此外，通过受试者工作特征（ROC）曲线分析评估 lncRNA-ATB 对 LNCa 的诊断价值。对患者进行 5 年随访，采用 Kaplan-Meier 检验进行生存分析。最后，采用 Cox 回归模型分析影响患者预后的因素。
lncRNA-ATB 在喉癌组织标本中的表达明显高于相应的正常组织，且与 T 分级和临床分期相关。使用 lncRNA-ATB 诊断喉癌的 ROC 曲线下面积（AUC）为 0.8672，诊断阈值为 3.895，灵敏度和特异度分别为 83.02%和 76.42%。此外，lncRNA-ATB 高表达患者的总生存率明显低于低表达组。同时，T 分级、临床分期和 lncRNA-ATB 是影响 LNCa 预后的三个独立因素。
lncRNA-ATB 在喉癌组织中呈高表达，不利于患者预后。因此，该分子标志物有可能成为 LNCa 患者诊断和预后预测的新生物标志物。
